KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of PYXS
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Pyxis Oncology, Inc. stock price down 0% on Friday
(Updated on Apr 26, 2024)

Sell candidate since Apr 10, 2024 Loss -15.35% PDF

No changes to the price of Pyxis Oncology, Inc. stock on the last trading day (Friday, 26th Apr 2024). During the last trading day the stock fluctuated 4.00% from a day low at $4.25 to a day high of $4.42. The price has fallen in 7 of the last 10 days and is down by -12.6% for this period.

The stock lies in the lower part of a very wide and weak rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $3.74 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 3.74% during the next 3 months and, with a 90% probability hold a price between $3.88 and $7.00 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

PYXS Signals & Forecast

There are few to no technical positive signals at the moment. The Pyxis Oncology, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $4.40 and $4.87. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Monday, April 08, 2024, and so far it has fallen -22.94%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point".

Support, Risk & Stop-loss for Pyxis Oncology, Inc. stock

Pyxis Oncology, Inc. finds support from accumulated volume at $4.16 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.170 between high and low, or 4.00%. For the last week the stock has had daily average volatility of 7.14%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (PYXS) For The Upcoming Trading Day Of Monday 29th

For the upcoming trading day on Monday, 29th we expect Pyxis Oncology, Inc. to open at $4.32, and during the day (based on 14 day Average True Range), to move between $3.83 and $4.77, which gives a possible trading interval of +/-$0.466 (+/-10.83%) up or down from last closing price. If Pyxis Oncology, Inc. takes out the full calculated possible swing range there will be an estimated 21.65% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $4.16 (3.26%) than the resistance at $4.48 (4.19%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Pyxis Oncology, Inc. stock A Buy?

The Pyxis Oncology, Inc. stock holds several negative signals and despite the positive trend, we believe Pyxis Oncology, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -2.449 Sell Candidate Unchanged

Predicted Opening Price for Pyxis Oncology, Inc. of Monday, April 29, 2024

Fair opening price April 29, 2024 Current price
$4.32 ( 0.542%) $4.30

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for PYXS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 4.49 4.49 %
R2 4.43 2.98 %
R1 4.39 2.05 %
Current price: 4.30
Support S1 4.26 -0.97 %
S2 4.22 -1.90 %
S3 4.15 -3.41 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 4.96 15.35 %
R2 4.74 10.23 %
R1 4.48 4.19 %
Current price 4.30
Support S1 4.16 -3.26%
S2 3.99 -7.21%
S3 3.71 -13.72%

FAQ

What is the symbol for Pyxis Oncology, Inc. Stock and on which exchange is it traded?
The symbol for Pyxis Oncology, Inc. is PYXS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Pyxis Oncology, Inc. Stock?
The Pyxis Oncology, Inc. stock holds several negative signals and despite the positive trend, we believe Pyxis Oncology, Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Pyxis Oncology, Inc. Stock?
Pyxis Oncology, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Pyxis Oncology, Inc. Stock.

What's the current price of Pyxis Oncology, Inc. Stock?
As of the end of day on the Apr 26, 2024, the price of an Pyxis Oncology, Inc. (PYXS) share was $4.30.

What is the 52-week high and low for Pyxis Oncology, Inc. Stock?
The 52-week high for Pyxis Oncology, Inc. Stock is $6.85 and the 52-week low is $1.35.

What is the market capitalization of Pyxis Oncology, Inc. Stock?
As of the Apr 26, 2024, the market capitalization of Pyxis Oncology, Inc. is 249.974M.

When is the next earnings date for Pyxis Oncology, Inc.?
The upcoming earnings date for Pyxis Oncology, Inc. is May 09, 2024.
Click to get the best stock tips daily for free!

About Pyxis Oncology, Inc.

Pyxis Oncology. Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap... PYXS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT